Payment overview · 2025
General Payments
$666.31
35 reported records · 13 companies
Healthcare provider profile · identity verified
William Marcrum, MD
Allopathic & Osteopathic Physicians|Family Medicine · TELL CITY, IN · NPI 1629051792
Verified facts
What the public records show
CMS Open Payments records show William Marcrum, MD received $666.31 in general payments during 2025 across 35 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $236.28 | 35.5% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.41 | 12.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.29 | 10.1% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $62.28 | 9.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.00 | 5.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.49 | 5.2% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $31.89 | 4.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.58 | 3.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.09 | 3.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.67 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.93 | 2.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.42 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.98 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $666.31 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $157.11 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.68 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $67.29 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $62.28 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $48.72 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.49 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.49 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 54 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
95 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
313 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 621 | 106 |
| Furosemide | Furosemide | 518 | 86 |
| Gabapentin | Gabapentin | 484 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 430 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 375 | 80 |
| Eliquis | Apixaban | 313 | 50 |
| Lisinopril | Lisinopril | 303 | 75 |
| Meloxicam | Meloxicam | 295 | 60 |
| Sertraline Hcl | Sertraline Hcl | 292 | 58 |
| Azelastine Hcl | Azelastine Hcl | 219 | 107 |
| Losartan Potassium | Losartan Potassium | 215 | 41 |
| Omeprazole | Omeprazole | 202 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 200 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 52 |
| Potassium Chloride | Potassium Chloride | 191 | 40 |
| Carvedilol | Carvedilol | 188 | 26 |
| Metformin Hcl | Metformin Hcl | 183 | 54 |
| Simvastatin | Simvastatin | 182 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 43 |
| Donepezil Hcl | Donepezil Hcl | 177 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 157 | 21 |
| Xarelto | Rivaroxaban | 155 | 13 |
| Memantine Hcl | Memantine Hcl | 149 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 143 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 33 |
| Allopurinol | Allopurinol | 141 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 34 |
| Farxiga | Dapagliflozin Propanediol | 139 | 22 |
| Lorazepam | Lorazepam | 134 | 32 |
| Tramadol Hcl | Tramadol Hcl | 130 | 47 |
| Levofloxacin | Levofloxacin | 127 | 72 |
| Trazodone Hcl | Trazodone Hcl | 126 | 34 |
| Montelukast Sodium | Montelukast Sodium | 124 | 24 |
| Jardiance | Empagliflozin | 120 | 15 |
| Buspirone Hcl | Buspirone Hcl | 117 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 103 | 23 |
| Mirtazapine | Mirtazapine | 102 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 102 | 17 |
| Myrbetriq | Mirabegron | 96 | 11 |
| Entresto | Sacubitril/Valsartan | 95 | 17 |
| Methylprednisolone | Methylprednisolone | 88 | 79 |
| Spironolactone | Spironolactone | 81 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 12 |
| Clonidine Hcl | Clonidine Hcl | 77 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 20 |
| Latanoprost | Latanoprost | 77 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 73 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 18 |
| Ozempic | Semaglutide | 70 | suppressed |
| Famotidine | Famotidine | 66 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 16 |
| Alendronate Sodium | Alendronate Sodium | 65 | 11 |
| Divalproex Sodium | Divalproex Sodium | 65 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 62 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 24 |
| Finasteride | Finasteride | 58 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | suppressed |
| Rybelsus | Semaglutide | 54 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 11 |
| Gemtesa | Vibegron | 52 | suppressed |
| Pregabalin | Pregabalin | 52 | 14 |
| Bupropion Xl | Bupropion Hcl | 51 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 51 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 11 |
| Alprazolam | Alprazolam | 48 | 11 |
| Lovastatin | Lovastatin | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Linzess | Linaclotide | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 36 |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 23 |
| Sucralfate | Sucralfate | 46 | 11 |
| Cefuroxime | Cefuroxime Axetil | 44 | 30 |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 31 |
| Glipizide Er | Glipizide | 43 | suppressed |
| Risperidone | Risperidone | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 13 |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Ondansetron Odt | Ondansetron | 38 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | 13 |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 31 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 27 |
| Mometasone Furoate | Mometasone Furoate | 29 | 22 |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Letrozole | Letrozole | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Glipizide | Glipizide | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Roflumilast | Roflumilast | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 11 |
| Cilostazol | Cilostazol | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 14 |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Betaxolol Hcl | Betaxolol Hcl | 11 | suppressed |
| Carbinoxamine Maleate | Carbinoxamine Maleate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $666.31 · 35 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, EVENITY, FANAPT, FARXIGA, LEQVIO, LYBALVI, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error